nontuberculous mycobacteria
Conditions
Interventions
Control group:anti-tuberculosis drugs
Experimental group:Tuberculosis drugs + kanglaogujin particles
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Comply with the diagnostic criteria of NTM lung disease, and confirmed that the pathogenic strain is Mycobacterium intracellulare or Mycobacterium abscessus by detecting the antigen mpd64, pmd medium and genetic test method of our laboratory; (2) Comply with the syndrome differentiation standard of Lung and Kidney Yin Deficiency and dominance of heat in the interior; (3) Chest CT examination revealed a hollow shadow or multiple lesions; (4) Aged 20 to 70 years old; (5) Those who are ineffective in regular anti-tuberculosis treatment; (6) Those who voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the inclusion criteria; (2) Those with serious infections; (3) Patients with severe hypertension, coronary heart disease, cardiac insufficiency, and abnormal liver and kidney function; (4) Mental patients cannot cooperate with the treatment; (5) Pregnant or lactating women and those who are known to be allergic to the composition of the drug; (6) Patients who are participating in other drug clinical trials; (7) If the medication is not prescribed and the doctor's advice is not followed, and impossible to judge whether the curative effect or clinical data incompletely affects the curative effect;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sputum NTM culture conversion rate and recurrence rate;Lesion absorption;Cavity closure rate;TCM symptom score;TCM single symptom score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Karnofsky score;Immune index;Blood routine;Biochemical Indicators; | — |
Countries
China
Contacts
Public ContactLixin Wang
Shanghai Pulmonary Hospital
Outcome results
None listed